Activity InformationRheum2Learn 2.0 is case-based fundamental clinical rheumatology education for residents. Each interactive activity includes three patient cases that focus on the care and assessment of individuals with rheumatologic diseases. In this activity, learn how to recognize symptoms and physical exam findings associated with spondyloarthritis. Explore the evaluation and management of conditions such as axial spondyloarthritis, psoriatic arthritis, and reactive arthritis, with attention to associated features like uveitis. Rheum2Learn SeriesThis activity is part of a series. See the other activities in the series below.Rheum2Learn 2.0: Crystalline ArthritisRheum2Learn 2.0: Infectious ArthritisRheum2Learn 2.0: Inflammatory MyopathiesRheum2Learn 2.0: Musculoskeletal DisordersRheum2Learn 2.0: Musculoskeletal ExaminationRheum2Learn 2.0: OsteoporosisRheum2Learn 2.0: OsteoarthritisRheum2Learn 2.0: Pediatric RheumatologyRheum2Learn 2.0: Rheumatic Manifestations of Systemic DiseaseRheum2Learn 2.0: Rheumatoid ArthritisRheum2Learn 2.0: Sjögren’s DiseaseRheum2Learn 2.0: Systemic Lupus ErythematosusRheum2Learn 2.0: Systemic SclerosisRheum2Learn 2.0: Systemic VasculitisRegistration is complimentary.Target AudienceResidents in training who may provide care for patients with rheumatic diagnoses in primary care, inpatient, critical care, and other clinical contexts.The activity may also be of interest to medical students, fellows in training, advanced practice providers, practicing physicians, and other health care professionals who seek to strengthen their clinical knowledge of rheumatic diseases.Learning ObjectivesUpon completion of this activity, participants should be able to:Differentiate inflammatory back pain from non-specific/mechanical back pain.Recognize the spectrum of axial spondyloarthritis.Remember imaging findings c/w axial spondyloarthritis.Identify the characteristic joint involvement patterns of psoriatic arthritis through careful history and physical examination.Recognize radiographic findings of psoriatic arthritis, including erosions with new bone formation, “pencil-in-cup” deformities, ankylosis, and sacroiliitis.Describe the major extra-articular and systemic manifestations of psoriatic arthritis—such as psoriasis, nail dystrophy, enthesitis, dactylitis, uveitis, and inflammatory bowel disease—and integrate these findings into a comprehensive assessment.Identify the typical time course for development of symptoms of reactive arthritis.Explain the utility of lab tests and imaging in diagnostic workup of reactive arthritis.Describe the initial steps in treatment of reactive arthritis, as well as when to refer to rheumatology and/or ophthalmology. CE & MOC InformationThis activity is not eligible for CME/MOC.Acknowledgement of Commercial SupportNo commercial support was provided for this activity.Educational Activity PoliciesSee ACR educational activity policies, including the online enduring activity refund policy.

Activity OverviewThe Rheumatology Review Course features key updates covering a wide range of rheumatology diseases. The activity contains eight lectures recorded at ACR Convergence 2024. Each session is approximately 45 minutes and includes a Q&A session.  The Review Course lectures include: To Be or Not to Behcet’s? Differentials for Oral UlcersPsoriatic Arthritis Management ReviewGeriatric Concerns in RheumatologyUpdates in SarcoidosisPain Management for the RheumatologistBeyond the Surface: Management of Calcinosis in Connective Tissue DiseasesCase-Based Approach to Metabolic Bone DiseaseChallenging Cases in Rheumatoid Arthritis Registration is discounted for ACR/ARP members. If you are not a member, consider joining the ACR/ARP.ACR/ARP Member: $399ACR/ARP Potential Member: $599 Target AudienceRheumatologists, physicians, primary care providers, fellows in training, physician assistants, advanced practice nurses, nurses, occupational therapists, physical therapists, pharmacists, residents, rheumatology interprofessionals, professionals interested in or engaged in rheumatology research.Learning ObjectivesUpon completion of this activity, participants should be able to:Apply the concept of complex aphthosisIdentify active disease in each PsA domainDescribe the unique aspects and considerations when caring for older adults with rheumatic diseasesRecognize areas of practice vulnerability to disparity, racism, and biasIdentify what calcinosis is in connective tissue diseasesIdentify presentation, work-up, and treatment for hypophosphatasiaDiscuss recent data informing therapeutic options available in an MTX-IR patientImplement strategies to address multi-morbidity in management of RA and D2T RACE & MOC InformationCMEACCME Accreditation StatementThe American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.  See the ACR's CME Mission Statement. For more information, download the AMA PRA Booklet.   AMA Designation Statement The American College of Rheumatology designates this Enduring Material for a maximum of 7.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.CME credit must be claimed by December 18, 2027, at 11:59 PM ET. MOCMOC Recognition Statement: American Board of Internal Medicine (ABIM)Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7.00 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. By completing this activity, you provide the ACR permission to share completion data with the ACCME and the certifying board.  After submitting a reflective statement with key takeaways from the activity, MOC points will be applied for ABIM diplomates to the ABIM diplomate number and date of birth provided when you registered. Points are sent nightly to ACCME and then transferred to the ABIM Physician Portal. Please allow at least 48 hours for points to display in the portal. MOC points must be claimed by December 18, 2027, at 11:59 PM ET. Financial Relationship DisclosuresACR Disclosure StatementIt is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org. In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.Nature of Financial RelationshipsAll individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:Advisor or review panel memberConsultantEmployeeOfficer or Board MemberGrant/research supportSpeaker/honoraria includes speaker’s bureau, symposia, and expert witnessIndependent contractorExecutive role and/or ownership interestRoyalties and/or patent beneficiaryIntellectual property/patentsStock options or bond holdings in a for-profit corporation or self-directed pension planPrivate investigatorExpert witnessEquity interestOther: specify details  None: Has no relevant financial relationship(s) with ineligible companies to disclose.All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated. Planning/Faculty Team MembersThe following planning / faculty team members have the following financial relationships with ineligible companies to disclose.Johannes Nowatzky, MD - Soligenix: Advisor or Review Panel Member (Ongoing)Ana-Maria Orbai, MD, MHS - AbbVie/Abbott: Grant/Research Support (Ongoing); Amgen: Grant/Research Support (Ongoing); Janssen: Grant/Research Support (Ongoing); UCB: Grant/Research Support (Ongoing)Namrata Singh, MD,MSc – Mustang Bio; ConsultantJulie Paik, MD, MHS - Alexion: Grant/Research Support (Ongoing); ArgenX: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing); Guidepoint: Consultant (Ongoing); Priovant: Grant/Research Support (Ongoing)Lesley Ann Saketkoo, MD, MPH - Kyverna: Grant/Research Support (Ongoing); Mallinckrodt: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing)Daniel Clauw, MD - Tonix: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Pfizer, Lilly; Lundbeck; Virios; Swing; Neurometrix; Consultant (Ongoing)Antonia Valenzuela, MD, MS – Board Member: SCTC (Secretary), Grant/Research Support: SCTC/PANLARLaura Carbone, MD, MS – Grant funded research; NIH/NIA, R01AG079118, Calculator for Length of Use of Bisphosphonates (CLUB); Department of Defense (DOD), SCI200001, Development of Novel Soluble Epoxide Hydrolase Inhibitotor as a Strategy for Treating Neuropathic Pain in Patients with Spinal Cord Injury; Off-label medication with supporting evidence will be discussed.Iain McInnes, PhD, FRCP - AbbVie: Consultant (Ongoing); Amgen: Consultant (Ongoing); AstraZeneca: Consultant (Ongoing); Bristol Myers Squibb: Consultant (Ongoing), Grant/Research Support (Ongoing); Cabaletta: Consultant (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Causeway Therapeutics: Consultant (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Compugen: Consultant (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Dextera: Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing); Moonlake: Consultant (Ongoing); NHS GGC: Officer or Board Member (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing); Sanofi: Consultant (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support (Ongoing); Versus Arthritis: Trustee Status (Ongoing)Review Team MembersThe following review team members have no relevant financial relationship(s) with ineligible companies to disclose. Adena Batterman, LCSW, MSWRebecca Manno, MD, MPHCarlos Ferreira, MAPlanning Team Members The following planning team members have no relevant financial relationship(s) with ineligible companies to disclose.Kai Sun, MD, MS, RhMSUSMyria Stanley, MS, DESSharon RossPriyanjali Pulipati, MBBSNoelle Rolle, MBBS, FACP, FACRAcknowledgement of Commercial SupportNo commercial support was provided for this activity.Educational Activity PoliciesSee ACR educational activity policies, including the online enduring activity refund policy.

Activity OverviewThe Advanced Rheumatology Course is a 19-activity series for advanced practice providers and other professionals who need a deeper dive into rheumatology.  The series covers how to assess and manage patients with rheumatic disease, develop strategies to integrate NP/PAs into rheumatology practice, and improve access to care for patients. The advanced information will help experienced practice providers function well in rheumatology and foster inter-professional collaboration. This activity reviews spondyloarthritis, including axial spondyloarthritis, psoriatic arthritis, reactive arthritis, and inflammatory bowel disease-associated arthritis.Advanced Rheumatology Course SeriesThis activity is part of a series. See the other activities in the series below.Advanced Rheumatology Course: All ActivitiesARC01: Musculoskeletal Structure And Function And Inflammation And ImmunityARC02: Framework for Clinical Decision Making in RheumatologyARC03: Laboratory Evaluation of Rheumatic DiseaseARC04: Imaging of ArthritisARC05: Coding and Practice IssuesARC06: Therapeutic Interventions And ResourcesARC07: OsteoarthritisARC08: RA and Seronegative Inflammatory ArthropathiesARC09: Systemic Lupus ErythematosusARC010: Systemic Inflammatory Conditions: Inflammatory MyopathyARC11: Vasculitis, Arteritis and PMRARC12: Crystal-Induced ArthropathiesARC13: Pain SyndromesARC14: SpondyloarthritisARC15: Infection-Related ArthritisARC16: Osteoporosis And Other Metabolic Bone DisordersARC17: Comprehensive Overview of Juvenile Idiopathic Arthritis (JIA)ARC18:Comprehensive Overview of Pediatric Connective Tissue Diseases (CTD)ARC19: Pediatric Noninflammatory Musculoskeletal PainRegistration is discounted for ACR/ARP members. If you are not a member, consider joining ACR/ARP.Target AudienceAdvanced practice nurses and physician assistants. Fellows-in training, residents, students, primary care providers, physical therapists, and researchers may also benefit.Learning ObjectivesUpon completion of this activity, participants should be able to: Define spondyloarthritis, the spectrum of conditions, and their common clinical featuresDifferentiate between mechanical back pain and inflammatory back painEnumerate the classification criteria for axial spondyloarthritis, peripheral spondyloarthritis, ankylosing spondylitis, and psoriatic arthritisDevelop a plan for how to investigate a patient with inflammatory back painDiscuss the epidemiology and pathogenesis of spondyloarthritisDescribe the clinical course and prognosis of ankylosing spondylitis, reactive arthritis, psoriatic arthritis (PA), and inflammatory bowel disease (IBD)-associated arthritisIntegrate in practice nonpharmacologic and pharmacologic disease management choicesCE & MOC InformationACCME Accreditation StatementThe American College of Rheumatology (ACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.AMA Designation StatementThe American College of Rheumatology designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.See the ACR's CME Mission Statement. For more information, download the AMA PRA Booklet.CME credit must be claimed by August 14, 2026, at 11:59 PM ET.Financial Relationship DisclosuresACR Disclosure StatementIt is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners' and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.Nature of Financial RelationshipsAll individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to: Advisor or review panel memberConsultantEmployeeOfficer or Board MemberGrant/research supportSpeaker/honoraria includes speaker’s bureau, symposia, and expert witnessIndependent contractorExecutive role and/or ownership interestRoyalties and/or patent beneficiaryIntellectual property/patentsStock options or bond holdings in a for-profit corporation or self-directed pension planPrivate investigatorExpert witnessEquity interestOther: specify detailsNone: Has no relevant financial relationship(s) with ineligible companies to disclose.All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated.AuthorsAtul Deodhar, MD -  AbbVie/Abbott528;  Amgen528;  BMS528;  Boheringer Ingelheim528;  Celgene528;  Gilead528;  Glapagos528;  Janssen528;  Lilly528;  Novartis528;  Pfizer528;  UCB528Anand Kumthekar, MD – No relevant financial relationships to disclosePlanners, Editors and ReviewersAbhijeet Danve, MD – AbbVie/Abbott1; Novartis1Anneke Smith – No relevant financial relationships to discloseSonam Kiwalkar, MD – No relevant financial relationships to discloseAcknowledgement of Commercial SupportThe project was supported by Grant number 1 NU58DP006908-03-00 – Component A; Developing and Disseminating Programs to Build Sustainable Lupus Awareness, Knowledge, Skills and Partnerships. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Department of Health and Human Services, Centers for Disease Control and Prevention.Educational Activity PoliciesSee ACR educational activity policies, including the online enduring activity refund policy.